Characteristics of patients with atrial fibrillation treated with direct oral anticoagulants and new insights into inappropriate dosing: results from the French National …
M Guenoun, S Cohen, M Villaceque, A Sharareh… - Europace, 2023 - academic.oup.com
Aims Since the introduction of direct oral anticoagulant (DOAC) for atrial fibrillation (AF)
therapy, inappropriate and/or underdosing of these drugs has been a major clinical …
therapy, inappropriate and/or underdosing of these drugs has been a major clinical …
Current status and outcomes of direct oral anticoagulant use in real-world atrial fibrillation patients―fushimi AF registry―
Y Yamashita, R Uozumi, Y Hamatani, M Esato… - Circulation …, 2017 - jstage.jst.go.jp
Background: The current status and outcomes of direct oral anticoagulant (DOAC) use have
not been widely evaluated in unselected patients with atrial fibrillation (AF) in the real world …
not been widely evaluated in unselected patients with atrial fibrillation (AF) in the real world …
Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and high thromboembolic risk. A systematic review
D Acanfora, MM Ciccone, P Scicchitano… - Frontiers in …, 2019 - frontiersin.org
Background: The aim of the study was to evaluate the efficacy and safety of direct oral
anticoagulants (DOACs) in a subgroup of patients with atrial fibrillation (AF), CHADS2 …
anticoagulants (DOACs) in a subgroup of patients with atrial fibrillation (AF), CHADS2 …
Impact of polypharmacy and P-glycoprotein-and CYP3A4-modulating drugs on safety and efficacy of oral anticoagulation therapy in patients with atrial fibrillation
RE Harskamp, M Teichert, WAM Lucassen… - … drugs and therapy, 2019 - Springer
Purpose To study whether polypharmacy or drug–drug interactions have differential effect
on safety and efficacy in patients treated with direct oral anticoagulants (DOACs) versus …
on safety and efficacy in patients treated with direct oral anticoagulants (DOACs) versus …
Characteristics and outcomes in patients with atrial fibrillation receiving direct oral anticoagulants in off-label doses
A Briasoulis, Y Gao, C Inampudi, P Alvarez… - BMC cardiovascular …, 2020 - Springer
Background We evaluated adherence to dosing criteria for patients with atrial fibrillation (AF)
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …
taking dabigatran or rivaroxaban and the impact of off-label dosing on thromboembolic and …
Comparative clinical outcomes between direct oral anticoagulants and warfarin among elderly patients with non-valvular atrial fibrillation in the CMS medicare …
A Amin, A Keshishian, O Dina, A Dhamane… - Journal of Thrombosis …, 2019 - Springer
Atrial fibrillation (AF) prevalence increases with age;> 80% of US adults with AF are aged≥
65 years. Compare the risk of stroke/systemic embolism (SE), major bleeding (MB), net …
65 years. Compare the risk of stroke/systemic embolism (SE), major bleeding (MB), net …
Off-label dosing of non–vitamin K antagonist oral anticoagulants and clinical outcomes in Asian patients with atrial fibrillation
YH Chan, TF Chao, SW Chen, HF Lee, YH Yeh… - Heart rhythm, 2020 - Elsevier
Background Off-label dosing non–vitamin K antagonist oral anticoagulants (NOACs) are
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …
commonly prescribed for Asian patients with atrial fibrillation (AF). Objective The purpose of …
The number of concomitant drugs and the safety of direct oral anticoagulants in routine care patients with atrial fibrillation
CJ van den Dries, S van Doorn, P Souverein… - TH Open, 2020 - thieme-connect.com
Background The benefit of direct oral anticoagulants (DOACs) versus vitamin K antagonists
(VKAs) on major bleeding was less prominent among atrial fibrillation (AF) patients with …
(VKAs) on major bleeding was less prominent among atrial fibrillation (AF) patients with …
Bleeding risk in nonvalvular atrial fibrillation patients receiving direct oral anticoagulants and warfarin: a systematic review and meta-analysis of observational studies
YP Wang, R Kehar, A Iansavitchene… - TH Open, 2020 - thieme-connect.com
Introduction In randomized trials in atrial fibrillation (AF) patients on direct oral
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …
anticoagulants (DOACs) have a lower risk of bleeding compared with warfarin. However …
Dose of direct oral anticoagulants and adverse outcomes in Asia
J Ohno, Y Sotomi, A Hirata, Y Sakata… - The American Journal of …, 2021 - Elsevier
The present study aimed to assess the associations between dosing of DOACs and
outcomes in patients with non-valvular atrial fibrillation (NVAF). Direct oral anticoagulants …
outcomes in patients with non-valvular atrial fibrillation (NVAF). Direct oral anticoagulants …